Wire · opportunities
Researcher shares key insights after highly anticipated drug trial falls short
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
The ZEUS trial tested ziltivekimab, an anti-inflammatory drug targeting IL-6, in patients with advanced atherosclerotic cardiovascular disease and chronic kidney disease but found no significant reduction in heart attack, stroke, or cardiovascular death compared to placebo. The trial enrolled a sicker, older population with complex comorbidities which may have limited the drug's effectiveness.
This Wire brief sits within Fusion42's coverage of Drug Discovery and Biotech.
◆ ◆ The Wire takeaway
Your drug development in cardiovascular inflammation just hit a major limit as treating a sicker, more complex patient group failed to improve outcomes. Reassess patient selection and explore alternative inflammatory targets before proceeding with similar costly trials.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics